Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: A review

European Journal of Pharmacology

Volumn 415, Issue 1, 2001, Pages 1-11

  De Beer, Evert L ^a   Bottone, Antonio E ^a   Voest, Emile E ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cardiac trabeculae; Cardiotoxicity; Doxorubicin; Transduction pathways

Indexed keywords

ANTHRACYCLINE; DNA FRAGMENT; DNA POLYMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; RAZOXANE;

APOPTOSIS; CARDIOTOXICITY; CELL NUCLEUS; CELL PROLIFERATION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG DNA BINDING; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; ENZYME SUBUNIT; HEART FAILURE; HUMAN; LONG TERM CARE; NUCLEIC ACID SYNTHESIS; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR GROWTH;

EID: 0035831158     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)00765-8     Document Type: Review

References (99)

1. Improvement of doxorubicin induced cardiomyopathy in rats treated with insulin-like growth factor I
2. 2+-ATPase gene transcription
3. Adriamycin Cardiotoxicity: Possible pathogenic mechanisms
4. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse
5. Anthracyclines enhance tension development in cardiac muscle by direct interaction with the contractile system
6. Impairment of the actin-myosin interaction in permeabilized cardiac trabeculae after chronic doxorubicin treatment
7. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions
8. Anthracycline-induced tension in permeabilized cardiac fibers: Evidence for the activation of the calcium release channel of sarcoplasmic reticulum
9. Contractile failure in chronic doxorubicin-induced cardiomyopathy
10. Effect of Ca2+ on cross-bridge turnover kinetics in skinned single rabbit psoas fibers: Implications for regulation of muscle contraction
11. Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization
12. Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release
13. Reduction of myofibrillar ATPase activity and isomyosin shift in delayed doxorubicin cardiotoxicity
14. The cardiotoxic antibiotic doxorubicin inhibits the Na+/Ca2+ exchange of dog heart sarcolemmal vesicles
15. Idarubicin: An anthracycline antineoplastic agent
16. An introduction to free radical biochemistry
17. Adriamycin (NSC-123127) cardiotoxicity: A clinicopathologic correlation
18. Variations in the relative mRNA levels of actins and myosin heavy chains do not produce corresponding differences in their proteins in the adult human heart
19. Effect of combined irradiation and doxorubicin treatment on cardiac function and antioxidant defenses in the rat
20. Exogenous doxorubicinol induces cardiotoxic effects in rats
21. Possible role of Prostaglandins in the pathogenesis of cardiomyopathies
22. Doxorubicin interacts directly with skinned single skeletal muscle fibres
23. Doxorubicin impairs crossbridge turnover in skinned trabeculae after acute and chronic treatment
24. Isolated mouse atrium as a model to study anthracycline cardiotoxicity: The role of the beta-adrenoceptor system and reactive oxygen species
25. Might adriamycinol contribute to adriamycin-induced cardiotoxicity?
26. Cardiovascular effects of doxorubicin-induced toxicity in the intact Lou/M Wsl rat and in isolated heart preparations
27. The complex Young's modulus of skeletal muscle fibre segments in the high frequency range determined from tension transients
28. Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model
29. Doxorubicin-induced cardiac toxicity
30. Alterations of mechanical parameters in chemically skinned preparations of rat myocardium as a function of isoenzyme pattern of myosin
31. The velocity of unloaded shortening and its relation to sarcomere length and isometric force in vertebrate muscle fibres
32. Maximum velocity of shortening related to myosin isoform composition in frog skeletal muscle fibres
33. Left ventricular functional capacity in the endurance-trained rodent
34. The cardiotoxicity of adriamycin and daunomycin in children
35. Anthracycline glycoside-membrane interactions
36. Myosin types in the human heart. An immunofluorescence study of normal and hypertrophied atrial and ventricular myocardium
37. Food restriction-induced transformations in cardiac functional and biochemical properties in rats
38. The antioxidant properties of five (O-β-hydroxyethyl)rutosides of the flavonoid mixture Venoruton
39. Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane
40. Altered expression of titin and contractile proteins in failing human myocardium
41. Comparison of the effectiveness of (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles
42. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in Netherlands
43. Relationship between myosin isoenzyme composition, hemodynamics, myocardial structure in various forms of human cardiac hypertrophy
44. Acute negative inotropic effect of adriamycin (doxorubicin)
45. Electrophoretic analysis of multiple forms of rat cardiac myosin: Effects of hypophysectomy and thyroxine replacement
46. The economy of isometric force development, myosin isoenzyme pattern and myofibrillar ATPase activity in normal and hypothyroid rat myocardium
47. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs
48. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro
49. The complete sequence of the human beta-myosin heavy chain gene and a comparative analysis of its product
50. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit
51. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer
52. Doxorubicin cardiotoxicity: Contractile changes after long-term treatment in the rat
53. The role of lipid peroxidation in acute doxorubicin-induced cardiotoxicity as studied in rat isolated heart
54. Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity
55. 2+-regulated force production in EGTA-treated muscles from rat heart
56. +-adenosine triphosphatase
57. Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo
58. Antineoplastic agent doxorubicin inhibits myogenic differentiation of C2 myoblasts
59. A clinicopathologic analysis of adriamycin cardiotoxicity
60. Interaction of adriamycin in vitro with cardiac myofibrillar proteins
61. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium
62. Identification and functional significance of troponin I isoforms in neonatal rat heart myofibrils
63. Complete sequence of human cardiac alpha-myosin heavy chain gene and amino acid comparison to other myosins based on structural and functional differences
64. Changes in essential myosin light chain isoform expression provide a molecular basis for isometric force regulation in the failing human heart
65. Dietary carbohydrates modify cardiac myosin isoenzyme profiles of semistarved rats
66. Myosin heavy chain gene expression in human heart failure
67. A protective effect of coenzyme Q10 on the adriamycin-induced cardiotoxicity in the isolated perfused rat heart
68. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses
69. Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits
70. Mechanism of adriamycin cardiotoxicity: Evidence for oxidative stress
71. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol
72. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure
73. Biphasic effects of doxorubicin on the calcium release channel from sarcoplasmic reticulum of cardiac muscle
74. Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin
75. Acute effects of doxorubicin on chronotropic and inotropic mechanisms in guinea pig atria
76. Increased mortality with cardiotoxic doses of Adriamycin after verapamil pretreatment despite prevention of myocardial calcium accumulation
77. Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis
78. Effects of chronic administration of doxorubicin on heart phospholipase A2 activity and in vitro synthesis and degradation of prostaglandins in rats
79. Determination of doxorubicin and doxorubicin-3-ol in rat heart
80. Various hypertrophic stimuli induce distint phenotypes in cardiomnyocites
81. 2+ binding and lipid peroxidation but depresses myocardial function
82. Subcellular effects of adriamycin in the heart: A concise review
83. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats
84. Myosin and why hearts fail
85. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer
86. Depression of force by phosphate in skinned skeletal muscle fibers of the frog
87. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy
88. Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles
89. Molecular mechanisms of myocardial remodeling
90. Doxorubicin: An antagonist of muscarinic receptors in guinea pig heart
91. Myosin light chain gene expression associated with disease states of the human heart
92. Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice
93. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors
94. Doxorubicin: Inotropic effects and inhibitory action on ouabain
95. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants
96. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat
97. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity
98. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives